Sino Biological, a biotechnology firm based in Shenzhen, California, has announced a CRO services partnership with Ainnocence, Inc. of San Jose, California. This partnership allows Ainnocence to obtain instant, effective, and precise antibodies to be developed and manufactured by Sino Biological for customers worldwide. Financial terms were not disclosed.
Sino Biologicals'' Chief Business Officer, Dr. Rob Burgess, said the addition of Ainnocences'' AI-based antibody-antigen binding prediction technology will enable Sino Biological to further enrich its antibody development CRO services offering, saving customers valuable development time and ensuring antibody-antigen binding affinities that meet their strict demands. We are looking forward to working with the Ainnocence team to develop and develop next-generation antibody technology.
Im confident that our partnership with Sino Biological will launch Ainnocences Biologics AI development applications in the biotech industry and ultimately accelerate clinical translation of cutting-edge medical technologies.